J. Jack Lee, Frank E. Harrell, Lisa M. LaVange, David J. Spiegelhalter
This Perspective discusses the importance of the US Food and Drug Administration’s draft guidance on the use of bayesian methods in clinical trials because it underscores its commitment to modernizing clinical research.